Ignite Creation Date:
2025-12-24 @ 7:48 PM
Ignite Modification Date:
2025-12-29 @ 4:10 PM
Study NCT ID:
NCT06445803
Status:
RECRUITING
Last Update Posted:
2024-06-06
First Post:
2024-06-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D054198', 'term': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma'}], 'ancestors': [{'id': 'D007945', 'term': 'Leukemia, Lymphoid'}, {'id': 'D007938', 'term': 'Leukemia'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D006402', 'term': 'Hematologic Diseases'}, {'id': 'D006425', 'term': 'Hemic and Lymphatic Diseases'}, {'id': 'D008232', 'term': 'Lymphoproliferative Disorders'}, {'id': 'D008206', 'term': 'Lymphatic Diseases'}, {'id': 'D007160', 'term': 'Immunoproliferative Disorders'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SEQUENTIAL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 48}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2024-05-31', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-06', 'completionDateStruct': {'date': '2026-12', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2024-06-01', 'studyFirstSubmitDate': '2024-06-01', 'studyFirstSubmitQcDate': '2024-06-01', 'lastUpdatePostDateStruct': {'date': '2024-06-06', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2024-06-06', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-10', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Incidence of Dose-limiting toxicity', 'timeFrame': 'Up to 28 days', 'description': 'Will be recorded and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0'}, {'measure': 'Incidence and severity of adverse events', 'timeFrame': 'Up to 15 years', 'description': 'Will be recorded and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0'}], 'secondaryOutcomes': [{'measure': 'Overall response rate', 'timeFrame': 'up to 15 years', 'description': 'Proportion of patients achieving a response'}, {'measure': 'Progression free survival', 'timeFrame': 'up to 15 years', 'description': 'Preparative regimen until the documentation of disease progression or death due to any cause, whichever occurs first.'}, {'measure': 'Overall survival', 'timeFrame': 'up to 15 years', 'description': 'Overall survival (OS) will be determined as the time from the start of the preparative regimen until death'}, {'measure': 'MRD negative response rates（ Acute Lymphoblastic Leukemia ）', 'timeFrame': 'up to 15 years', 'description': 'MRD status post infusion，MRD will be performed utilizing flow cytometry or PCR.'}, {'measure': 'Persistence of CD19/CD22 CAR-T cells blood, bone marrow', 'timeFrame': 'up to 15 years', 'description': 'pk properties of CD19/CD22 CAR-T'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['CAR-T therapy'], 'conditions': ['Acute Lymphoblastic Leukemia, in Relapse', 'Acute Lymphoblastic Leukemia With Failed Remission', 'B-cell Lymphoma Refractory', 'B-cell Lymphoma Recurrent']}, 'descriptionModule': {'briefSummary': 'This study examines the safety, tolerability and preliminary efficacy of anti-CD19 /CD22 CAR T cells (KQ-2002)manufactured on-site in adults with relapsed or refractory CD19+ B cell acute lymphoblastic leukemia or CD19+ B cell non Hodgkin lymphoma.', 'detailedDescription': 'Patients will undergo screening, leukapheresis (cell collection), lymphodepleting chemotherapy with fludarabine and cyclophosphamide, followed by the anti-CD19 KQ-2002 CAR T cell infusion. The lymphodepleting chemotherapy is administered over 3 days IV to prepare the body for the CAR T cells. The CAR-T cells are infused between 2-7 days after the last dose of chemotherapy. Patients will be followed for two years after the cell infusion on the study and for up to 15 years to monitor for potential long term side effects of cell therapy.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Male or female,≥18 years old;\n* Histologically confirmed diagnosis of B-ALL or B-NHL(meeting one of the following conditions):\n\n(B-NHL)\n\n1. Second or greater relapse (CD20 regimens must be included) OR\n2. Refractory to first-line chemotherapy or relapse within 1 year OR\n3. Relapse within 1 year of auto-HSCT.\n4. With measurable or evaluable lesions（Dose expansion cohort） (B-ALL)\n\na. Relapse within 12 months of complete remission on first treatment OR b. Relapse after second-line treatment OR c. Relapse after auto HST OR d. Failure to achieve CR/CRi at the end of induction therapy OR e. Ph+ ALL intolerance to TKI or refractory or relapse after treatment with at least two and more TKIs.\n\n* ECOG 0\\~2\n* Estimated survival time ≥ 12 weeks;\n* Main tissues and organs function well.\n\nExclusion Criteria:\n\n* Subjects will be excluded related to the following prior therapy criteria:Prior treatment with bendamustine-containing or fludarabine;Anti-T-cell monoclonal antibody, donor lymphocyte infusion, and CNS radiotherapy within 8 weeks; Chemotherapy, lenalidomide, bortezomib within 2 weeks; vincristine within 1 week; glucocorticoids (prednisone ≥7.5 mg/d or equivalent) within 72 h\n* Active or latent hepatitis B or active hepatitis C (test within 8 weeks of screening), or any uncontrolled infection at screening\n* Uncontrolled, symptomatic, intercurrent illness including but not limited to angina pectoris, cerebrovascular accident or transient ischemia (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), New York Heart Association (NYHA) classification of ≥ Class III congestive heart failure, severe arrhythmia poorly controlled by medications, hepatic, renal, or metabolic disorders, and hypertension that is uncontrolled by standard therapy；\n* active bleeding, or venous thromboembolic event\n* Autoimmune diseases (e.g., Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, etc.) that result in end-organ damage or require systemic application of immunosuppressive drugs\n* Central nervous system (CNS) disease or symptoms of CNS involvement\n* Pregnant or nursing (lactating) women\n* Presence of Grade 2 or above non-hematologic toxicity , alopecia and grade 2 neuropathy excluded\n* Any Iinappropriate conditions in the opinion of the PI ."}, 'identificationModule': {'nctId': 'NCT06445803', 'briefTitle': 'CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL', 'organization': {'class': 'OTHER', 'fullName': 'Fudan University'}, 'officialTitle': "A Preliminary Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetic Profile of KQ-2002 (CD19/CD22 CAR-T) in Adults With Recurrent or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma", 'orgStudyIdInfo': {'id': 'KQ-2002-XC001'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Dose escalation', 'description': 'CD19/CD22-CAR-transduced T cells at escalating doses (0.5\\~5.0 ×10\\^6 cells/kg)', 'interventionNames': ['Biological: KQ-2002 CAR-T cells （CD19/CD22 CAR T-Cells）']}, {'type': 'EXPERIMENTAL', 'label': 'Dose expansion', 'description': 'CD19/CD22-CAR-transduced T cells at MTD or highest dose administered', 'interventionNames': ['Biological: KQ-2002 CAR-T cells （CD19/CD22 CAR T-Cells）']}], 'interventions': [{'name': 'KQ-2002 CAR-T cells （CD19/CD22 CAR T-Cells）', 'type': 'BIOLOGICAL', 'description': 'CD19/CD22 cells will be infused on Day1 after induction chemotherapy regimen.\n\nLymphodepleting chemotherapy:3 days of IV chemotherapy with fludarabine and cyclophosphamide.\n\nFludarabine 30 mg/m2/day IV x 4 days (days -5 through -3) Cyclophosphamide 500 mg/m2/day IV x 2 days (days -5 and-3)', 'armGroupLabels': ['Dose escalation', 'Dose expansion']}]}, 'contactsLocationsModule': {'locations': [{'zip': '360000', 'city': 'Nanchang', 'state': 'Jiangxi', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Fei Li, MD', 'role': 'CONTACT', 'email': 'lifeigcp@2022@163.com', 'phone': '13970038386'}, {'name': 'Fei Li, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'The First Affiliated Hospital of Nanchang University;', 'geoPoint': {'lat': 28.68396, 'lon': 115.85306}}, {'zip': '200032', 'city': 'Shanghai', 'state': 'Shanghai Municipality', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Rong Tao, MD', 'role': 'CONTACT', 'email': 'rtao@shca.org.cn', 'phone': '8621-64175590'}, {'name': 'Wenhao Zhang, MD', 'role': 'CONTACT', 'email': 'zwhl98@foxmail.com', 'phone': '8621-64175590'}, {'name': 'Rong Tao, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Fudan University Shanghai Cancer Center', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}], 'centralContacts': [{'name': 'Weijing Zhang', 'role': 'CONTACT', 'email': 'JJYIN555@163.com', 'phone': '021-64175590', 'phoneExt': '88503'}], 'overallOfficials': [{'name': 'Rong Tao, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Fudan University'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Rong Tao', 'class': 'OTHER'}, 'collaborators': [{'name': 'Novatim Immune Therapeutics (Zhejiang) Co., Ltd.', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorTitle': 'Chief physician', 'investigatorFullName': 'Rong Tao', 'investigatorAffiliation': 'Fudan University'}}}}